Basic Information
| LncRNA/CircRNA Name | PVT1 |
| Synonyms | NA |
| Region | GRCh38_8:127794533-128101253 |
| Ensemble | ENSG00000249859 |
| Refseq | NR_003367 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | ovarian cancer |
| ICD-0-3 | C56.9 |
| Methods | qPCR, Luciferase reporter assay, in vitro knockdown |
| Sample | ovarian cancer cell lines, A2780 and SKOV3 |
| Expression Pattern | up-regulated |
| Function Description | PVT1 was the most amplifed gene in ovarian cancer patients, and it was highly correlated with poor survival outcomes. Knockdown of PVT1 caused decreased cell viability, metabolic activity, and smaller proportion of S-phase cells. PVT1 directly bound to miR-140 and acted as a microRNA sponge, while transcription of PVT1 was regulated by the transcription factor FOXO4. |
| Pubmed ID | 31222482 |
| Year | 2019 |
| Title | Amplifcation of lncRNA PVT1 promotes ovarian cancer proliferation by binding to miR-140 |
External Links
| Links for PVT1 | GenBank HGNC NONCODE |
| Links for ovarian cancer | OMIM COSMIC |